Objective Individuals with immunocompromised (IC) conditions are at a higher risk of developing herpes zoster (HZ) than IC-free individuals. This study assessed the healthcare resource utilisation (HCRU) burden and costs, of HZ in IC and IC-free individuals ≥18 years of age (YOA). Methods We conducted an observational retrospective study in a cohort of IC (n=621 588) and IC-free (n=621 588) individuals, matched by age, gender and General Practitioner practice region, contributing to the Clinical Practice Research Datalink database from 2000 to 2012 and linked to the Hospital Episode Statistics inpatient data. HCRU (ie, primary and secondary care consultations, hospital inpatient stays and treatment prescriptions) was analysed from 7 days before to: (1) 30, (2) 365 days after the HZ diagnosis date for individuals with (1) HZ only (no postherpetic neuralgia (PHN)) and (2) individuals with HZ and PHN only. Healthcare costs were computed by multiplying the number of units of resources used by the unit costs, summed across all HCRU categories to obtain a total cost per subject. Values were expressed in 2014 UK pound sterling (£) and presented for HZ cases overall, stratified by age (ie,(50)(51)(52)(53)(54)(55)(56)(57)(58)(59)(60)(61)(62)(63)(64)(65)(66)(67)(68)(69)(70)(71)(72)(73)(74)(75)(76)(77)(78)(79) and IC status. results The percentage of HZ cases requiring hospitalisation was higher in IC individuals (2.7% vs 0.4% in IC and IC-free individuals aged 18-49 YOA, respectively and 9.5% vs 7.5% in IC and IC-free individuals aged ≥80 YOA, respectively). Similarly, HZ-related mean treatment costs per subject were higher in IC individuals (£189 vs £104 in IC and IC-free individuals aged 18-49 YOA, respectively and £557 vs £401 in IC and IC-free individuals aged ≥80 YOA, respectively). Costs varied considerably by IC condition. Conclusions Individuals with IC conditions, have a high burden of HZ, associated with an increased risk of HZ and high HZ-related healthcare costs.
AbstrACt
Objective Individuals with immunocompromised (IC) conditions are at a higher risk of developing herpes zoster (HZ) than IC-free individuals. This study assessed the healthcare resource utilisation (HCRU) burden and costs, of HZ in IC and IC-free individuals ≥18 years of age (YOA). Methods We conducted an observational retrospective study in a cohort of IC (n=621 588) and IC-free (n=621 588) individuals, matched by age, gender and General Practitioner practice region, contributing to the Clinical Practice Research Datalink database from 2000 to 2012 and linked to the Hospital Episode Statistics inpatient data. HCRU (ie, primary and secondary care consultations, hospital inpatient stays and treatment prescriptions) was analysed from 7 days before to: (1) 30, (2) 365 days after the HZ diagnosis date for individuals with (1) HZ only (no postherpetic neuralgia (PHN)) and (2) individuals with HZ and PHN only. Healthcare costs were computed by multiplying the number of units of resources used by the unit costs, summed across all HCRU categories to obtain a total cost per subject. Values were expressed in 2014 UK pound sterling (£) and presented for HZ cases overall, stratified by age (ie, 18-49, 50-59, 60-69, 70-79 and ≥80 YOA) and IC status. results The percentage of HZ cases requiring hospitalisation was higher in IC individuals (2.7% vs 0.4% in IC and IC-free individuals aged 18-49 YOA, respectively and 9.5% vs 7.5% in IC and IC-free individuals aged ≥80 YOA, respectively). Similarly, HZ-related mean treatment costs per subject were higher in IC individuals (£189 vs £104 in IC and IC-free individuals aged 18-49 YOA, respectively and £557 vs £401 in IC and IC-free individuals aged ≥80 YOA, respectively). Costs varied considerably by IC condition. Conclusions Individuals with IC conditions, have a high burden of HZ, associated with an increased risk of HZ and high HZ-related healthcare costs.
IntrOduCtIOn
Varicella zoster virus cell-mediated immunity (VZV-CMI) inhibits the development of herpes zoster (HZ). 1 Therefore, if for any reason VZV-CMI declines, the risk of HZ increases. Reasons for VZV-CMI decline can include, increasing age and immune suppression. VZV-CMI is not optimal in individuals with immunocompromised (IC) conditions and the age-specific incidence and severity of HZ greatly increases in IC patients due to underlying illness (eg, Human immunodeficiency virus infection) or immunosuppressive therapies for autoimmune disease, malignancy, or organ transplantation. 2 The incidence and severity of HZ is marked with an increase in people ≥50 years of age strengths and limitations of this study ► The study is an observational retrospective descriptive study presenting the healthcare resource utilisation and costs associated with herpes zoster (HZ) in both immunocompromised (IC) and IC-free populations aged ≥18 years of age in England. ► The IC population included 621 588 individuals who were registered in the Clinical Practice Research Datalink from January 2000 to March 2012 with ≥12 month follow-up before being diagnosed with any of the selected 16 IC conditions and matched to the Hospital Episode Statistics database by age, gender and practice location to extract the IC-free population (n=621 588). ► The particularity of this study is that the design allowed calculation of IC condition prevalence rates, HZ incidence rates and occurrence of HZ-related healthcare utilisation and costs at individual level in the same predefined population(s). ► This key study will provide data to be used in economic analyses to evaluate the value of vaccination in reducing the burden of HZ in IC populations. ► A limitation of the study is that the diagnoses were derived from administrative codes, which are recognised to be subject to miscoding or under-coding and are not validated against medical charts.
Open access (YOA) due to an age-related decline in immunity (ARDI). In the United Kingdom (UK) the incidence of HZ rises from 7.1 per 1000 person-years (PY) among 60-64 year olds to 12.2 per 1000 PY among individuals aged ≥85 YOA. 3 Further to the impact of ARDI, a study by Forbes et al in 2014 investigated the increased risk for HZ in the UK population, associated with autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus; and chronic conditions such as diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease and asthma. 2 In addition to the increased risk of HZ in the various IC conditions these populations also experience increased severity of disease. In a study in Canada, Drolet et al reported that individuals with an impaired immune status had HZ severity of illness scores, as measured by the Zoster Brief Pain Inventory, which were twice as high as individuals with normal immune function. 4 5 In a study in the USA, Yawn et al reported that although 8% of HZ cases were in individuals who were immunocompromised, these individuals represented 23.8% of the total HZ-related costs. 6 The increase in healthcare costs was associated with higher rates of postherpetic neuralgia (PHN) and non-pain complications in this group of individuals. 6 This study aims to estimate the healthcare resource utilisation of HZ in selected IC populations and in an IC-free (ie, immunocompetent) population aged ≥18 YOA in England. The clinical burden of disease epidemiological results of the study are reported elsewhere, 7 and may be summarised as follows: the prevalence of IC conditions increased from 7.6% in individuals aged 18-44 YOA to 42.2% in individuals aged ≥80 YOA; the incidence rate of HZ in the IC cohort was 3.5/1000 PY in individuals aged 18-49 YOA increasing to 12.6/1000 PY in individuals aged ≥80 YOA. In this manuscript, we focus on the healthcare resource utilisation and costs associated with HZ in both IC and IC-free populations.
MethOds
The study was conducted as an observational retrospective descriptive study (e-track number: 201615), in a cohort of eligible matched IC and IC-free populations (aged ≥18 YOA). The IC population included individuals who were registered in the Clinical Practice Research Datalink (CPRD) from January 2000 to March 2012 with ≥12 month follow-up before being diagnosed with any of the selected 16 IC conditions (see online supplementary material). The CPRD IC population cohort was linked to the Hospital Episode Statistics (HES) database and matched, using a 1:1 ratio, to a cohort of CPRD-HES linked IC-free population (n=621 588), by age, gender and practice location. 8 Individuals with a missing date of IC diagnosis were excluded from the study population. Clinical diagnoses were based on READ codes used in CPRD and with the International Classifications of Diseases-10 th revision (ICD-10) codes in the HES database. The study protocol was approved by the Independent Scientific Advisory Committee (ISAC) for the Medicines and Healthcare Products Regulatory Agency database research (ISAC protocol number 14_222R). The study was conducted in accordance with all applicable regulatory requirements, with the Guidelines for Good Pharmacoepidemiology Practices, 9 all applicable patient privacy requirements and the guiding principles of the Declaration of Helsinki.
The matched IC and IC-free cohorts were followed up from the index date until the earliest of the following events: transfer out of the practice date, the last GP practice collections date, death date or the end of the study. 7 Healthcare resource data associated with an incident HZ episode during the study follow-up were extracted for IC and matched IC-free CPRD-HES-linked individuals. Only reported records (resource utilisation) with available event dates during the individuals' eligibility period Figure 1 Lay language summary.
Open access and those that occurred 7 days before the initial HZ onset date, up to 365 days after the initial HZ onset date, were extracted. Consequently, individuals who recorded the first PHN event date after 365 days post HZ event date were classified as not having PHN.
Patient and public involvement
This is a retrospective database analysis carried out following ethical committee approval. No patient or the public was involved in the study design or in the recruitment or the conduct of this study. No specific dissemination of study results to participants was done. However, we provided a lay language summary contextualising the results and potential clinical research relevance and impact in figure 1. Practitioners (GPs) or others in the GP practice); HES secondary care outpatient visits (HES outpatient events); and HES inpatient hospitalizations (HES inpatient events).
For each patient, healthcare costs stratified by subcategory of interest (HES Inpatient Hospitalizations; HES Outpatient consultations/visits; CPRD Ambulatory Visits; CPRD Other Ambulatory Visits; CPRD Prescriptions) were computed by multiplying units of resource use by their unit costs. These were then summed over all resource use categories to obtain a total cost for each patient. Values were expressed in 2014 UK pound sterling (£).
healthcare resource costs For each patient, the cost of each prescription was calculated by merging the product code, package type and prescribed quantity with the associated standard package size and unit cost. The unit cost of a product in a prescription instance (ie, one distinct record in the CPRD therapy) was calculated using the cost described in the British National Formulary (BNF), 2015 (as listed price if included or indicative price based on price in BNF).
Ambulatory visits included consultations with GPs and nurses in primary or community care. Visits included consultations at the practice or at the home of the patient, during working hours and out of hours. Consultations for which no clinical intervention was recorded were not included in the cost estimate for GP practice related healthcare utilisation, for example: information technology data migration, administrative recording of received information. Administrative resource use in primary care was considered, including time on the phone, writing reports, referrals, etc. A referral to secondary care noted in a patient's record, per se, was not allocated the cost of the secondary care appointment. The most conservative option for the cost per unit as included in the Personal Social Services Research Unit (PSSRU) Costs of Health and Social Care, 2014 were applied eg, GP consultation costs excluded qualification, direct staff care and travel costs. 10 Where specific costs for 2013/14 were not available, 2012/13 costs, were adjusted by applying the Hospital and Community Health Services inflation index. 10 Administration costs were based on unit costs as stated in the PSSRU, 2014.
Inpatient hospitalizations related to HZ were derived from HES data. Hospital Outpatient resource utilisation concerned HZ related referrals for non-inpatient hospital consultations, derived from the HES Outpatient data. Additionally, visits to the Accident and Emergency (A&E) department in hospitals were also recorded and costed. Inpatient hospitalisation costs were based on the average cost per episode using HES data for 2013/14 (calculated from the total average payment by result spell cost and the average number of episodes per spell). Hospital outpatient costs were sourced from National Tariff costs (2014) for specific consultant led outpatient consultations; conservative costs were allocated that is wherever applicable costs for first attendance by a single professional appointment were used.
11 Costs allocated to A&E visits were based on the cost of a category 3 investigation with category 1-3 treatment. Figure 3 and table 2 present the overall healthcare costs by CPRD-HES-linked matched IC cohort and age group for the analysis period 7 days prior to 365 days post initial HZ onset. The costs increase with age and are consistently higher in the IC cohort compared with the IC-free cohort. Although the absolute cost difference between IC and IC-free individuals increases with age from £85.5 in individuals aged 18-49 YOA to £156.1 in individuals aged ≥80 YOA the relative difference is higher in younger individuals (ie, 75.8%-99.2% in <70 YOA) compared with older individuals (ie, 38.9%-57.6% in ≥70 YOA). It is also noteworthy that the means are consistently higher than medians, and as is common for healthcare cost data, the distribution is skewed to the right. See online supplementary table 5 and online supplementary figures 1 and 2 provide additional data on healthcare Costs for the analysis period 7 days prior to 90 days post initial HZ onset. Figure 4 presents the overall healthcare costs by each IC condition in the CPRD-HES-linked matched IC and IC-free cohort by age group for the analysis period 7 days prior to 365 days post initial HZ onset. For all IC conditions, the costs were higher than those for the IC-free group, in particular for the hematopoietic stem cell transplantation (HSCT), haematological malignancies and solid organ transplantations (SOT) conditions. In general, there was a similar trend of increasing costs with increasing age-groups. A few outliers were observed due to small sample sizes. For example, only 3 and 8 individuals aged ≥70 YOA were included in the HIV and HSCT groups, respectively. Similarly, in total only 207 and 271 individuals with autoimmune thyroiditis and SOT were included, respectively. Online supplementary table 6 presents the non-HZ related hospital inpatient stay for the period 7 days to 365 days post initial-HZ onset. The mean number of non-HZ related hospitalisations were consistently higher in IC patients compared with and IC-free patients and increased with age.
dIsCussIOn In this study, we presented the healthcare resource utilisation and costs associated with HZ in both IC and IC-free populations using large electronic health record databases in the UK. An important feature of this study was that the design enabled the calculation of IC condition prevalence rates, HZ incidence rates and occurrence of HZ-related healthcare utilisation and costs at individual level in the same predefined population(s), see Yanni et al for further detail on epidemiological outcomes. 7 In this study, every effort was made to include only resources directly related to HZ. For example, only hospitalised patients were included who had an ICD-10 HZ diagnosis identified in the HES database. Similarly, only medications potentially related to HZ treatment were included (see online supplementary tables 2 and 4). HZ-related mean treatment costs per patient were higher in IC individuals (£189 vs £104 in IC and IC-free Open access individuals aged 18-49 YOA, respectively increasing to £557 vs £401 in IC and IC-free individuals aged ≥80 YOA, respectively). Previous studies of healthcare costs of HZ in the UK, included a small study, which estimated the mean healthcare costs per HZ patient, from an National Health Services perspective, of £85.6 and £400.9 in individuals aged <65 YOA and ≥65 YOA, respectively. 12 A later UK study that used the HES and the health improvement network databases, estimated the mean cost of treating a HZ patient to be £65.5 in the first month of diagnosis, with patients aged ≥70 YOA having a mean cost of £83 in the first month and £15.80 in months 2 and 3. 13 The costs of treating individuals with PHN were much higher, that is, mean cost per patient was estimated to be £921 in all individuals and £909.60 in individuals aged ≥70 YOA. 13 Another study evaluated mean healthcare costs (excluding hospitalisation costs) to be £75.63 per HZ patient with mean direct costs for treating PHN episodes (PHN pain occurring or persisting for 3 months) of £340.04.
14 These values augmented with hospitalisation costs were used as inputs in a cost-effectiveness model evaluating a HZ vaccine using the population of England and Wales. 3 The costs estimated by van Hoek et al are consistent with the values estimated in our study for IC-free individuals by age group. 3 In a previous study, mean prescription costs per HZ patient were reported to be £40.52.
14 In our study, the mean prescription costs per HZ patient ranged from £19.7 to £40.8 depending on the age group, IC status and analysis period included. Our study aimed to include only medications considered to be directly related to HZ; that is, excluded medications that may be linked to IC conditions (eg, aspirin, analgesic creams as they could be used primarily to reduce pain from other conditions). This restriction and the introduction of generic versions of medications such as acyclovir, gabapentin (and derivatives of gabapentin) which resulted in lower prices, contributed to the reduced overall medication costs reported in this study.
Many studies on HCRU and costs include a number of days prior to diagnosis, for example, 14 or 21 days, as there may be a delay in diagnosis and HCRU may be used prior to diagnosis. 6 15 In this analysis, costs of HZ only cases were assessed during the period 7 days prior to 30 days post HZ onset, although it is recognised that HZ episodes can last for longer. The costs of PHN were analysed over two time-periods, ie, (1) 7 days prior to 90 days post HZ onset and (2) 7 days prior to 365 days post HZ onset. The rationale for the time periods studied was that using analysis period 1 alone could lead to an underestimation of PHN costs whereas using analysis period 2 only could overestimate these costs. The most frequently used definition of PHN is: pain persisting or appearing at least 90 days following rash onset. The median duration of PHN has been reported to be 10.3 and 12.9 months in individuals aged ≤69 and ≥70 YOA respectively, 16 and is likely to be longer in individuals who are immunocompromised. 5 The healthcare costs associated with PHN and complications were higher than those for individuals with HZ only. However, as reported elsewhere, when considering the overall cost of disease at a population level, the overall healthcare-associated cost is higher for HZ only. 17 This is primarily a result of the higher incidence rates of HZ only.
Few studies have investigated healthcare resource utilisation and costs in IC individuals. Schroder et al carried out a study using the German Pharmacoepidemiological Research Database, which consists of claims data from four statutory health insurances. 18 They reported that during the quarter of the HZ diagnosis or during the two following quarters, 10% of all HZ patients with an IC condition were hospitalised (with a HZ diagnosis), whereas among IC-free HZ patients, 4.2% were hospitalised. White et al reported that in their study using the US Market Scan Research 
Open access
Database, direct medical costs were nearly twice as high in IC patients compared with IC-free patients. 19 Li et al carried out a study using the US Truven Health MarketScan Commercial and Medicare Supplemental Insurance databases. 15 They concluded that patients with the studied IC conditions (ie, HIV, SOT, bone marrow or stem cell transplant and cancer) had significantly higher healthcare utilisation and cost when developing HZ than their comparable matches without HZ. Insurance databases include not only the healthcare resource utilisation but also costs. In the CPRD and HES Databases only the resource utilisation is captured. As such the overall costs need to be calculated by assigning unit costs to the resource utilisation. There are advantages however of using the CPRD and HES in that the databases offer more diversity than might be observed using insurance databases, the latter of which may be somewhat limited by bias associated with factors such as age, race and income. A strength of the CPRD database is that it is considered to be broadly representative of the characteristics of patients and GP practices in the UK. 20 21 This study has several limitations. Diagnoses were derived from administrative codes, which are recognised to be subject to miscoding or under-coding and are not validated against medical charts.
22 Increasing healthcare resource utilisation and cost is likely to be related to increased severity of IC conditions. In a study, Schroder et al categorised individuals as low IC and high IC. 18 However, insufficient details are recorded in the CPRD and HES databases to allow adequate definition of patients' severity of immunosuppression for example, laboratory parameters, immunosuppressive medication details such as chemotherapy. In addition, many IC individuals had prescriptions that included more Open access than one immunosuppressing medicine. In this study we selected 16 IC conditions in our definition of an IC population but perhaps other researchers would select different IC conditions. As such our study is exploratory in nature and was not intended to be definitive.
COnClusIOn
Immunosuppression is known to be associated with an increased risk of HZ in the UK. 2 7 In this descriptive analysis, involving a large representative national data source, the results suggest that individuals with IC conditions were associated with higher HZ related healthcare utilisation and costs than IC-free individuals. 6 7 15 The results from this study could be used in economic analyses to evaluate the value of vaccination in reducing the burden of HZ in these populations.
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